Skip to content
LodeRx
Get started
Compounded Tirzepatide Shortage Rules in 2026: What Changed and What Stayed the Same — hero
Blog· glp-1· tirzepatide· compounding

Compounded Tirzepatide Shortage Rules in 2026: What Changed and What Stayed the Same

FDA removed tirzepatide from its shortage list in late 2024. Here is what that meant for compounded tirzepatide access heading into 2026, and what did not change.

8 min read

Compounded tirzepatide options changed twice in a short window: first during the well-documented 2022–2024 shortage, then again once the FDA declared that shortage resolved. If you are trying to figure out whether compounded tirzepatide is still available in 2026, the honest answer is yes, but only under narrower conditions than existed two years ago, and only when a licensed clinician documents why a patient needs it.

Table of contents

What Actually Happened to the Tirzepatide Shortage

The FDA maintains a public drug shortage database that tracks supply status for specific drugs and dosage forms, including tirzepatide injection. That database is not a symbolic list; it is the legal trigger for whether pharmacies can compound a drug at scale.

In October 2024, the FDA first indicated that manufacturer supply data supported resolving the tirzepatide shortage. Outsourcing facilities and patient advocacy groups pushed back on that determination, arguing supply had not caught up with demand in every region. By December 2024, the FDA confirmed the shortage designation had been resolved after a further review of supply from the brand manufacturer.

Shortage status matters because federal law ties 503A and 503B compounding privileges for a specific drug to whether that drug is officially listed as in shortage. Once tirzepatide came off that list, the legal basis for broad, non-patient-specific compounding narrowed with it.

FDA's Shortage Resolution Timeline From October 2024 Through 2026

Litigation from compounding-industry groups temporarily complicated the shortage determination in late 2024, according to court filings covered by Reuters. Compounders argued the FDA's supply data did not reflect real-world availability at the pharmacy counter.

The FDA's final position, reflected in its ongoing drug shortage database updates, has held that tirzepatide injection is not in shortage heading into 2026. No broad reversal of that determination has occurred since; the day-to-day compounding rules described in this article track directly back to that late-2024 resolution.

What to remember: shortage status is not a one-time event. The FDA can add a drug back to the shortage list if supply data changes again, so the rules here reflect the current listing, not a permanent guarantee.

What Changed for 503A Pharmacies Once the Shortage Was Resolved

Under the Federal Food, Drug, and Cosmetic Act, 503A pharmacies may compound an essentially copy of a commercially available drug only in narrow circumstances once that drug is no longer listed as in shortage. Tirzepatide's shortage resolution moved it into that narrower category.

Mass, non-patient-specific compounding of tirzepatide that simply mirrored the commercial product's strength and formulation is no longer broadly permitted the way it was during the active shortage window. Pharmacies now need a documented, patient-specific clinical reason for compounding, such as:

  • A different strength than what is commercially available.
  • A non-standard dosage form the commercial product does not offer.
  • A documented inactive-ingredient allergy the commercial product cannot accommodate.

This is the core operational shift providers and patients need to understand: compounded tirzepatide did not disappear, but blanket compounding did.

What Stayed the Same: The Patient-Specific Necessity Exception

The FD&C Act's Section 503A patient-specific exception has not been repealed or narrowed further since the 2024 shortage resolution. A 503A partner pharmacy can still compound tirzepatide for an individual patient when a licensed prescriber documents a specific medical need that the commercially available product cannot meet.

State pharmacy board oversight of 503A compounding, already in place before the shortage, continues unchanged in 2026. That oversight layer exists independent of shortage status and has not shifted with the FDA's determination.

LegitScript Healthcare Merchant Certification, the accreditation LodeRx holds, is a compliance and business-practice certification. It is not FDA approval and not a medical endorsement of any compounded formulation; it speaks to how a healthcare merchant operates, not to whether any specific medication is approved or effective.

Understanding which pathway a pharmacy operates under explains why some compounding options tightened in 2026 while others did not.

Pathway Who it serves Shortage-dependent? Oversight
503A pharmacy Individual patients, patient-specific prescription Yes, for essentially-copy formulations State boards of pharmacy, FDA
503B outsourcing facility Bulk compounding for clinics and offices, no patient-specific script required Yes, more restrictive once resolved FDA registration, cGMP inspection

503B outsourcing facilities generally lost more compounding latitude than 503A pharmacies once the shortage was resolved, because 503B compounding without a patient-specific prescription depends heavily on active shortage status. Once that status ended, the legal room for 503B facilities to keep producing essentially-copy tirzepatide shrank more sharply than it did for 503A pharmacies.

LodeRx patients are dispensed through RxAve and other 503A partner pharmacies, which operate under the patient-specific prescription model rather than bulk 503B production. That is a structural detail worth understanding before comparing options, since it is the difference between a pathway that survived the shortage resolution largely intact and one that did not.

How This Affects Patients Considering Compounded Tirzepatide in 2026

Patients should not assume compounded tirzepatide is automatically available simply because it was widely offered during the 2022–2024 shortage period. A clinician now has to document why a specific patient needs a compounded version rather than the commercially available product, and that documentation is not a formality; it is the legal basis for the prescription existing at all.

Every compounded tirzepatide prescription written for a LodeRx patient is evaluated by a state-licensed EliteCare clinician before any prescription is written. LodeRx itself does not diagnose, prescribe, or dispense medication. Once a clinician determines a documented need exists, the prescription is compounded and dispensed by a 503A partner pharmacy, not manufactured or compounded by LodeRx.

Plain-language takeaway: compounded tirzepatide in 2026 is legal and available in specific, documented clinical situations. It is not a general substitute for the commercially available product, and it is not marketed here as FDA-approved for compounded formulations.

Questions to Ask a Provider Offering Compounded Tirzepatide in 2026

Before starting with any telehealth provider, it is worth asking direct questions about how the prescription and pharmacy relationship actually works:

  1. Does a licensed clinician document a specific medical reason for compounding rather than prescribing the commercial product?
  2. Which 503A or 503B pharmacy performs the actual compounding and dispensing, and is that disclosed in writing?
  3. Is the compounded product described accurately as compounded, never as FDA-approved, and never as identical to a brand-name molecule?
  4. What labs or intake steps does the clinician require before writing a prescription?
  5. Is the platform's certification, such as LegitScript, presented accurately as a compliance credential rather than a medical endorsement?

A provider that cannot answer these plainly is worth a second look before you hand over health information.

FAQ

Is compounded tirzepatide still legal in 2026? Compounded tirzepatide remains legal under specific conditions in 2026. Since the FDA confirmed the tirzepatide shortage was resolved in late 2024, 503A pharmacies can compound it only when a licensed clinician documents a patient-specific medical need the commercial product cannot meet, per FDA guidance on the FD&C Act's compounding provisions.

Why did compounded tirzepatide become harder to get after 2024? Federal law ties broad 503A and 503B compounding of an essentially-copy formulation to a drug's official shortage status. Once the FDA's drug shortage database listed tirzepatide as resolved in December 2024, mass compounding that simply mirrored the commercial product's strength lost its legal basis, though patient-specific compounding continued.

What is the difference between 503A and 503B compounding for tirzepatide? A 503A pharmacy compounds for an individual patient under a specific prescription and is regulated primarily by state pharmacy boards. A 503B outsourcing facility compounds in bulk for clinics without a patient-specific prescription and is FDA-registered; 503B compounding depends more heavily on active shortage status than 503A does.

Does LegitScript certification mean compounded tirzepatide is FDA-approved? No. LegitScript Healthcare Merchant Certification, which LodeRx holds, is a compliance and business-practice accreditation. It does not mean a compounded medication is FDA-approved, and it is not a medical endorsement of any specific formulation or outcome.

Can I still get compounded tirzepatide through LodeRx in 2026? An EliteCare clinician evaluates each patient individually to determine whether a documented medical need supports a compounded prescription. If appropriate, the prescription is compounded and dispensed by a 503A partner pharmacy such as RxAve. LodeRx does not diagnose, prescribe, or dispense medication itself.

If you are trying to work out whether your own situation fits the patient-specific necessity standard described above, the next concrete step is to review your history and goals with a licensed clinician rather than guess from general rules. You can start by reviewing how compounded medications work on LodeRx, explore LodeRx's tirzepatide program overview, or read how the LodeRx intake and clinician evaluation process works before requesting an evaluation.

Compounded tirzepatide is not FDA-approved for compounded formulations; only the brand-name molecule carries FDA approval. LodeRx holds LegitScript Healthcare Merchant Certification, a compliance and business-practice accreditation, not a medical endorsement.